Tackling issues spanning health, green energy and material science, the EIC Scaling Club aims to grow its member companies’ revenues by 40% per year. Its mission is for 20% of its members to become unicorns – privately-owned companies worth over USD 1 billion. 

Elypta’s participation will accelerate the development of its diagnostics platform, which could provide clinicians with the tools necessary to redefine cancer diagnostics. At the core of Elypta’s MIRAM platform are human glycosaminoglycans (GAGs) – these are crucial components of tumor microenvironments, and several recent studies have demonstrated their potential as cancer biomarkers. Elypta believes that the GAGome – the makeup of GAGs found in the body – is often altered years before cancer develops and, through effective testing, patients at higher risk of developing cancer can be stratified from general populations for more frequent testing. 

“The whole team at Elypta is delighted to be part of the club. With multiple clinical studies in the works – including EU Horizon 2020 funded AURORAX-0087A , which aims to support registration of the first ever urine test for detection of recurring kidney cancer – Elypta is well positioned to scale significantly. I look forward to the coming year, and all the work we will do with the club,” says Elypta’s CEO, Karl Bergman.